<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01113008</url>
  </required_header>
  <id_info>
    <org_study_id>PI-0327/2008</org_study_id>
    <nct_id>NCT01113008</nct_id>
  </id_info>
  <brief_title>Remote Ischemic Postconditioning in Humans</brief_title>
  <official_title>Remote Ischemic Postconditioning. Can it Prevent Myocardial Injury During Percutaneous Coronary Intervention?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Virgen de la Victoria</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FUNDACIÓN IMABIS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Red Temática de Investigación Cooperativa en Enfermedades Cardiovasculares</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitario Virgen de la Victoria</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the phenomenon of remote ischemic post-conditioning in
      humans. The minor myocardial damage associated with percutaneous revascularization procedures
      may be attenuated by producing controlled ischemia in the arms immediately after carrying out
      these procedures (remote ischemic post-conditioning). The justification and design of this
      clinical trial has been reported: Cardiology. 2011;119(3):164-9.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Percutaneous coronary intervention (PCI) has taken on an important role in the treatment of
      ischemic heart disease in recent years. However, the beneficial effects of revascularization
      are partly shadowed by post-reperfusion injury, which accounts for up to half the size of the
      reperfused myocardial infarct. Several drugs and procedures exist that might protect against
      this phenomenon. One of the most controversial of these strategies, which has shown promising
      results in experimental animal models, is remote ischemic post-conditioning. This involves
      inducing ischemia at a site remote from the heart after an ischemic coronary lesion to reduce
      the resulting myocardial infarct size.

      The myocardial damage produced by ischemia-reperfusion associated with PCI is a known short-
      and long-term prognostic factor, and is associated with a greater risk of death, myocardial
      infarction and revascularization during the follow-up.

      Our aim is to assess the phenomenon of remote ischemic post-conditioning in patients
      undergoing PCI, in whom the acute insult on the myocardium is determined by the angioplasty
      itself. Additionally, we aim to evaluate this phenomenon in a subgroup of diabetic patients,
      among whom the effectiveness of protective measures against post-reperfusion damage is more
      questioned.

      We have designed a randomized, single-blinded interventional study involving 320 patients
      (40% diabetics) who are to undergo elective PCI. At the end of the angioplasty procedure, the
      patients assigned to remote ischemic post-conditioning will undergo three 5-minute cycles of
      ischemia using a blood-pressure cuff at 200 mmHg, placed on the non-dominant arm, interrupted
      twice for 5 minutes with the cuff deflated. In the control group the procedure will be
      limited to placing a deflated blood-pressure cuff (pressure: 0 mmHg) for 25 minutes.

      The infarct size will be analyzed from an enzyme curve of troponin I and CK-MB values 0, 8,
      16 and 24 hours after the procedure (primary endpoint). Measurements will also be taken of pH
      and lactate in the baseline sample (0 hours) and at 8 hours, and ultrasensitive C-reactive
      protein at 0 and 24 hours as a contrasted marker of inflammation in ischemic heart disease.

      The follow-up, planned for one year, will seek to determine clinically interesting variables
      (secondary endpoint), such as readmission due to acute coronary syndrome, heart failure or
      major arrhythmic events and overall and cardiovascular mortality.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Increase of Troponin at 24 Hours</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Readmission Due to Acute Coronary Syndrome</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Mortality</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">266</enrollment>
  <condition>Myocardial Reperfusion Injury</condition>
  <arm_group>
    <arm_group_label>Remote postcondtioning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to remote ischemic postconditioning (randomized controlled trial)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Remote ischemic postconditioning</intervention_name>
    <description>Patients assigned to remote ischemic postconditioning will undergo three 5-minute cycles of ischemia using a blood-pressure cuff at 200 mmHg, placed on the non-dominant arm, interrupted twice for 5 minutes with the cuff deflated</description>
    <arm_group_label>Remote postcondtioning</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Control group</intervention_name>
    <description>In the control group the procedure will be limited to placing a deflated blood-pressure cuff (pressure: 0 mmHg) for 25 minutes.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients undergoing PCI due to stable angina

          2. Patients undergoing PCI due to unstable angina

          3. Patients undergoing PCI due NON Q acute myocardial infarction with normal troponin at
             inclusion moment (less than 1 ng/ml)

        Exclusion Criteria:

          1. Acute myocardial infarction during the previous two weeks

          2. Chronic renal failure with baseline creatinine above 3 mg/dL

        4. Collateral circulation of the revascularized artery (Rantrop &gt;0) 5. Prior treatment with
        glibenclamide. 6. Inability to receive follow-up, blood test or lack of informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel F Jiménez-Navarro, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servicio Cardiología, Hospital Universitario Virgen de la Victoria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>JENNINGS RB, SOMMERS HM, SMYTH GA, FLACK HA, LINN H. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol. 1960 Jul;70:68-78.</citation>
    <PMID>14407094</PMID>
  </reference>
  <reference>
    <citation>Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007 Sep 13;357(11):1121-35. Review.</citation>
    <PMID>17855673</PMID>
  </reference>
  <reference>
    <citation>Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986 Nov;74(5):1124-36.</citation>
    <PMID>3769170</PMID>
  </reference>
  <reference>
    <citation>Jiménez-Navarro M, Gómez-Doblas JJ, Hernández García JM, Alonso-Briales J, García Alcántara A, Gómez G, Rodriguez-Bailón I, de Teresa E. Does angina pectoris the week before protect against first acute myocardial infarction in patients with diabetes mellitus? Am J Cardiol. 2002 Jul 15;90(2):160-2.</citation>
    <PMID>12106849</PMID>
  </reference>
  <reference>
    <citation>Iliodromitis EK, Kyrzopoulos S, Paraskevaidis IA, Kolocassides KG, Adamopoulos S, Karavolias G, Kremastinos DT. Increased C reactive protein and cardiac enzyme levels after coronary stent implantation. Is there protection by remote ischaemic preconditioning? Heart. 2006 Dec;92(12):1821-6. Epub 2006 Jul 19.</citation>
    <PMID>16855045</PMID>
  </reference>
  <reference>
    <citation>Ali ZA, Callaghan CJ, Lim E, Ali AA, Nouraei SA, Akthar AM, Boyle JR, Varty K, Kharbanda RK, Dutka DP, Gaunt ME. Remote ischemic preconditioning reduces myocardial and renal injury after elective abdominal aortic aneurysm repair: a randomized controlled trial. Circulation. 2007 Sep 11;116(11 Suppl):I98-105.</citation>
    <PMID>17846333</PMID>
  </reference>
  <reference>
    <citation>Hausenloy DJ, Mwamure PK, Venugopal V, Harris J, Barnard M, Grundy E, Ashley E, Vichare S, Di Salvo C, Kolvekar S, Hayward M, Keogh B, MacAllister RJ, Yellon DM. Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet. 2007 Aug 18;370(9587):575-9.</citation>
    <PMID>17707752</PMID>
  </reference>
  <reference>
    <citation>Hoole SP, Heck PM, Sharples L, Khan SN, Duehmke R, Densem CG, Clarke SC, Shapiro LM, Schofield PM, O'Sullivan M, Dutka DP. Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) Study: a prospective, randomized control trial. Circulation. 2009 Feb 17;119(6):820-7. doi: 10.1161/CIRCULATIONAHA.108.809723. Epub 2009 Feb 2.</citation>
    <PMID>19188504</PMID>
  </reference>
  <reference>
    <citation>Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L'Huillier I, Aupetit JF, Bonnefoy E, Finet G, André-Fouët X, Ovize M. Postconditioning the human heart. Circulation. 2005 Oct 4;112(14):2143-8. Epub 2005 Sep 26.</citation>
    <PMID>16186417</PMID>
  </reference>
  <reference>
    <citation>Andreka G, Vertesaljai M, Szantho G, Font G, Piroth Z, Fontos G, Juhasz ED, Szekely L, Szelid Z, Turner MS, Ashrafian H, Frenneaux MP, Andreka P. Remote ischaemic postconditioning protects the heart during acute myocardial infarction in pigs. Heart. 2007 Jun;93(6):749-52. Epub 2007 Apr 20.</citation>
    <PMID>17449499</PMID>
  </reference>
  <reference>
    <citation>Gritsopoulos G, Iliodromitis EK, Zoga A, Farmakis D, Demerouti E, Papalois A, Paraskevaidis IA, Kremastinos DT. Remote postconditioning is more potent than classic postconditioning in reducing the infarct size in anesthetized rabbits. Cardiovasc Drugs Ther. 2009 Jun;23(3):193-8. doi: 10.1007/s10557-009-6168-5.</citation>
    <PMID>19255833</PMID>
  </reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2010</study_first_submitted>
  <study_first_submitted_qc>April 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2010</study_first_posted>
  <results_first_submitted>January 11, 2015</results_first_submitted>
  <results_first_submitted_qc>January 11, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 21, 2015</results_first_posted>
  <last_update_submitted>January 11, 2015</last_update_submitted>
  <last_update_submitted_qc>January 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myocardial Reperfusion Injury/mortality</keyword>
  <keyword>Coronary angioplasty</keyword>
  <keyword>Reperfusion</keyword>
  <keyword>Myocardial Reperfusion Injury/prevention &amp; control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>Myocardial Reperfusion Injury</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control Group</title>
          <description>Control group : In the control group the procedure will be limited to placing a deflated blood-pressure cuff (pressure: 0 mmHg) for 25 minutes.</description>
        </group>
        <group group_id="P2">
          <title>Remote Postcondtioning</title>
          <description>Patients assigned to remote ischemic postconditioning (randomized controlled trial)
Remote ischemic postconditioning : Patients assigned to remote ischemic postconditioning will undergo three 5-minute cycles of ischemia using a blood-pressure cuff at 200 mmHg, placed on the non-dominant arm, interrupted twice for 5 minutes with the cuff deflated</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Remote Postcondtioning</title>
          <description>Patients assigned to remote ischemic postconditioning (randomized controlled trial)
Remote ischemic postconditioning: Patients assigned to remote ischemic postconditioning will undergo three 5-minute cycles of ischemia using a blood-pressure cuff at 200 mmHg, placed on the non-dominant arm, interrupted twice for 5 minutes with the cuff deflated</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Control group: In the control group the procedure will be limited to placing a deflated blood-pressure cuff (pressure: 0 mmHg) for 25 minutes.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="118"/>
            <count group_id="B2" value="114"/>
            <count group_id="B3" value="232"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.8" spread="10.1"/>
                    <measurement group_id="B2" value="64.4" spread="9.3"/>
                    <measurement group_id="B3" value="64.6" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Increase of Troponin at 24 Hours</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Control group : In the control group the procedure will be limited to placing a deflated blood-pressure cuff (pressure: 0 mmHg) for 25 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Remote Postcondtioning</title>
            <description>Patients assigned to remote ischemic postconditioning (randomized controlled trial)
Remote ischemic postconditioning : Patients assigned to remote ischemic postconditioning will undergo three 5-minute cycles of ischemia using a blood-pressure cuff at 200 mmHg, placed on the non-dominant arm, interrupted twice for 5 minutes with the cuff deflated</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Increase of Troponin at 24 Hours</title>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.478" lower_limit="0.2839" upper_limit="0.6726"/>
                    <measurement group_id="O2" value="0.476" lower_limit="0.2842" upper_limit="0.6686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Readmission Due to Acute Coronary Syndrome</title>
        <time_frame>12 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Control group : In the control group the procedure will be limited to placing a deflated blood-pressure cuff (pressure: 0 mmHg) for 25 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Remote Postcondtioning</title>
            <description>Patients assigned to remote ischemic postconditioning (randomized controlled trial)
Remote ischemic postconditioning : Patients assigned to remote ischemic postconditioning will undergo three 5-minute cycles of ischemia using a blood-pressure cuff at 200 mmHg, placed on the non-dominant arm, interrupted twice for 5 minutes with the cuff deflated</description>
          </group>
        </group_list>
        <measure>
          <title>Readmission Due to Acute Coronary Syndrome</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiovascular Mortality</title>
        <time_frame>12 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Control group : In the control group the procedure will be limited to placing a deflated blood-pressure cuff (pressure: 0 mmHg) for 25 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Remote Postcondtioning</title>
            <description>Patients assigned to remote ischemic postconditioning (randomized controlled trial)
Remote ischemic postconditioning : Patients assigned to remote ischemic postconditioning will undergo three 5-minute cycles of ischemia using a blood-pressure cuff at 200 mmHg, placed on the non-dominant arm, interrupted twice for 5 minutes with the cuff deflated</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiovascular Mortality</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Control Group</title>
          <description>Control group : In the control group the procedure will be limited to placing a deflated blood-pressure cuff (pressure: 0 mmHg) for 25 minutes.</description>
        </group>
        <group group_id="E2">
          <title>Remote Postcondtioning</title>
          <description>Patients assigned to remote ischemic postconditioning (randomized controlled trial)
Remote ischemic postconditioning : Patients assigned to remote ischemic postconditioning will undergo three 5-minute cycles of ischemia using a blood-pressure cuff at 200 mmHg, placed on the non-dominant arm, interrupted twice for 5 minutes with the cuff deflated</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Mortality</sub_title>
                <description>Mortality due to cardiovascular event in study follow up</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Manuel Jiménez Navarro</name_or_title>
      <organization>H Virgen de la Victoria</organization>
      <phone>951 032 354 ext 0034</phone>
      <email>jimeneznavarro@secardiologia.es</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

